<html><head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head><body>
<span style="position:absolute; border: gray 1px solid; left:0px; top:50px; width:612px; height:792px;"></span>
<div style="position:absolute; top:50px;"><a name="1">Page 1</a></div>
<div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:108px; width:499px; height:476px;"><span style="font-family: Arial,Bold; font-size:10px">Source of Support:</span><span style="font-family: Arial; font-size:10px"> Funding was provided by The Coca-Cola Company.  By contractual agreement, 
<br>all decisions regarding the content of the manuscript—including design, analysis, and interpretation—
<br>rest solely with the authors.  
<br> 
<br></span><span style="font-family: Arial,Bold; font-size:11px"> 
<br>Oral Abstract 11 - Lowering Glucose and Insulin Responses to a Starchy Staple: 
<br>From Formulation to Flux</span><span style="font-family: Arial; font-size:11px">  
<br></span><span style="font-family: Arial,Bold; font-size:11px">(David Mela, The Netherlands) 
<br></span><span style="font-family: Arial; font-size:7px"> 
<br></span><span style="font-family: Arial,Italic; font-size:10px">Hanny M Boers</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, Theo H van Dijk</span><span style="font-family: Arial,Italic; font-size:6px">2</span><span style="font-family: Arial,Italic; font-size:10px">, Coby Eelderink</span><span style="font-family: Arial,Italic; font-size:6px">3</span><span style="font-family: Arial,Italic; font-size:10px">, Harry Hiemstra</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, Anne-Roos Hoogenraad</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, 
<br>Katrina MacAulay</span><span style="font-family: Arial,Italic; font-size:6px">4</span><span style="font-family: Arial,Italic; font-size:10px">, Peter Murray</span><span style="font-family: Arial,Italic; font-size:6px">4</span><span style="font-family: Arial,Italic; font-size:10px">, Harry PF Peters</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, Marion G Priebe</span><span style="font-family: Arial,Italic; font-size:6px">3</span><span style="font-family: Arial,Italic; font-size:10px">, Jack WM Seijen ten Hoorn</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, 
<br>Mirjam AM Vente-Spreeuwenberg</span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">, David J Mela</span><span style="font-family: Arial,Italic; font-size:6px">1*</span><span style="font-family: Arial,Italic; font-size:10px"> 
<br></span><span style="font-family: Arial,Italic; font-size:6px">1</span><span style="font-family: Arial,Italic; font-size:10px">Unilever R&amp;D, Vlaardingen NL; </span><span style="font-family: Arial,Italic; font-size:6px">2</span><span style="font-family: Arial,Italic; font-size:10px">Dept Laboratory Medicine and </span><span style="font-family: Arial,Italic; font-size:6px">3</span><span style="font-family: Arial,Italic; font-size:10px">Center for Medical Biomics, 
<br>University Medical Center Groningen, Groningen NL; </span><span style="font-family: Arial,Italic; font-size:6px">4</span><span style="font-family: Arial,Italic; font-size:10px">Unilever R&amp;D, Sharnbrook UK 
<br>E-Mail: david_mela@unilever.com 
<br></span><span style="font-family: Arial; font-size:7px"> 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Objective:</span><span style="font-family: Arial; font-size:10px"> There is growing endorsement for the benefits of lowering acute post-prandial glucose 
<br>(PPG) and insulin (PPI) responses to carbohydrate-rich staples. This work describes the selection and 
<br></span><span style="font-family: Arial; font-size:10px">effects of incorporating viscous fibres and an alternative starch source into the wheat-based flour 
<br>(‘atta’) used for making flatbreads, a widely-consumed carbohydrate source in South Asia.  
<br></span><span style="font-family: Arial,Bold; font-size:10px">Methods:</span><span style="font-family: Arial; font-size:10px"> From existing literature, </span><span style="font-family: Arial,Italic; font-size:10px">in vitro</span><span style="font-family: Arial; font-size:10px"> glucose release, and product feasibility, guar gum (GG), 
<br>konjac mannan (KM) and chickpea flour (CPF) were prioritized for clinical testing in freshly prepared 
<br>flatbreads. Trial 1 (balanced-order incomplete block design, n=38 UK subjects) compared 10 modified 
<br>atta formulations (2/4/6% GG; 2/4% KM; 15% CPF, and 10 or 15% CPF plus 2 or 4% GG) to an 
<br>existing full-fibre commercial product reference. Based on those results, Trial 2 (full crossover design, 
<br>n=50 Indian subjects) tested 3 formulations (15% CPF + 2/3/4% GG). Trial 3 then measured effects of 
<br>CPF+GG on glucose fluxes using dual isotope labelling (n=12 Dutch males). 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Results:</span><span style="font-family: Arial; font-size:10px"> In Trial 1, 6% GG, 4% KM, and 15% CPF plus 2 or 4% GG produced significant (p&lt;0.01), 
<br>≥30% reductions in PPG 2-hr incremental area under the curve. A model with 3 </span><span style="font-family: Arial,Italic; font-size:10px">in vitro</span><span style="font-family: Arial; font-size:10px"> parameters 
<br>closely predicted these results (R</span><span style="font-family: Arial; font-size:6px">2
<br></span><span style="font-family: Arial; font-size:10px">marked PPI reductions, both GG dose-related. Trial 3 showed these reductions in PPG and PPI 
<br>occurred with modest reductions in glucose uptake and clearance, and much more substantial 
<br>suppression of hepatic glucose production rate.</span><span style="font-family: Arial,Bold; font-size:10px">  
<br>Conclusions: </span><span style="font-family: Arial; font-size:10px">1) The combined CPF+GG formulations significantly reduce PPG and PPI; 2) </span><span style="font-family: Arial,Italic; font-size:10px">in vitro</span><span style="font-family: Arial; font-size:10px"> 
<br>assays can aid in prioritizing formulations for clinical testing; and 3) the dose-related PPG-lowering 
<br>effects of GG+CPF predominantly reflect post-absorptive effects rather than rates of glucose uptake.  
<br></span><span style="font-family: Arial,Bold; font-size:10px">Protocol Registration:</span><span style="font-family: Arial; font-size:10px"> ClinicalTrials.gov Identifier: NCT01734590 (Trial 3) 
<br></span><span style="font-family: Arial,Bold; font-size:10px">Funding source:</span><span style="font-family: Arial; font-size:10px"> Unilever 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:222px; top:473px; width:309px; height:11px;"><span style="font-family: Arial; font-size:6px">adj</span><span style="font-family: Arial; font-size:10px">=0.98). Trial 2 largely confirmed the results for PPG also with 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:598px; width:10px; height:20px;"><span style="font-family: ABCDEE+MV Boli; font-size:20px"> 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:634px; width:10px; height:20px;"><span style="font-family: ABCDEE+MV Boli; font-size:20px"> 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:669px; width:10px; height:20px;"><span style="font-family: ABCDEE+MV Boli; font-size:20px"> 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:704px; width:10px; height:20px;"><span style="font-family: ABCDEE+MV Boli; font-size:20px"> 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:740px; width:10px; height:20px;"><span style="font-family: ABCDEE+MV Boli; font-size:20px"> 
<br></span></div><div style="position:absolute; border: textbox 1px solid; writing-mode:lr-tb; left:56px; top:781px; width:13px; height:24px;"><span style="font-family: ABCDEE+Calibri; font-size:11px">52 
<br> 
<br></span></div><span style="position:absolute; border: black 1px solid; left:93px; top:296px; width:129px; height:0px;"></span>
<div style="position:absolute; top:0px;">Page: <a href="#1">1</a></div>
</body></html>
